PubMed Health⌕ Search

Biomedical subjects

H Havanka-Kanniainen

Publications and source records attributed to H Havanka-Kanniainen.

8 recordsLinked to original sources
PubMed1989

Treatment of acute migraine attack: ibuprofen and placebo compared.

The efficacy of ibuprofen in comparison with that of placebo was assessed in the treatment of acute migraine attacks. The material consisted of 40 migraine patients. Each treatment period continued for five migraine attacks. The initial dose of ibuprofen was 800 mg, with additional 400 mg taken if and when needed. The mean duration of migraine attacks treated with ibuprofen was significantly shorter than the duration of migraine attacks treated with placebo. Need for supplementary medication was also significantly lower in the ibuprofen-treated migraine attack group. Ibuprofen was well tolerated and no marked side effects were reported during the trial.

Adolescent↗
PubMed1987

Efficacy of nimodipine in comparison with pizotifen in the prophylaxis of migraine.

The efficacy of nimodipine in comparison with that of pizotifen was assessed in the prophylaxis of migraine in a double-blind cross-over study, in which a double-dummy technique was also utilized. The study was carried out on 43 migraine patients, of whom 15 had classic and 28 had common migraine. A 4-week run-in placebo period preceded the drug treatments, the drug treatments lasted 12 weeks, and there was a washout placebo period of 4 weeks between nimodipine and pizotifen treatments. The dosages used were 40 mg three times daily for nimodipine and 0.5 mg three times daily for pizotifen. Both nimodipine and pizotifen proved to be better than placebo, the number of migraine attacks showing a significant reduction. There was no difference between nimodipine and pizotifen in antimigrainous efficacy, but there were fewer side effects during the nimodipine period. The results suggest that nimodipine is an effective drug for the prophylaxis of migraine, with few side effects and therapeutic efficacy equal to that of pizotifen.

Adolescent↗
PubMed1985

Efficacy of nimodipine in the prophylaxis of migraine.

The efficacy of nimodipine in the prophylaxis of migraine was assessed in a double-blind, placebo-controlled, cross-over study carried out on 33 patients, 20 of whom suffered from classic and 13 from common migraine. Four patients dropped out, but not as a result of the side effects of the drug. The duration of drug treatment was 8 weeks. The dosage used was 30 mg four times daily. Nimodipine proved to be better than placebo, the number of migraine attacks and severity of headache showing a significant reduction. The drug was well tolerated and no marked side effects were noted. The results suggest that nimodipine is a useful new prophylactic drug for migraine, but further studies are needed before its final value can be evaluated.

Adult↗